Easterly Investment Partners LLC Has $1.12 Million Stock Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Easterly Investment Partners LLC lowered its stake in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 80.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 61,454 shares of the life sciences company's stock after selling 245,700 shares during the quarter. Easterly Investment Partners LLC owned approximately 0.08% of Integra LifeSciences worth $1,117,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. CWM LLC increased its stake in Integra LifeSciences by 50.8% in the 2nd quarter. CWM LLC now owns 1,262 shares of the life sciences company's stock worth $37,000 after purchasing an additional 425 shares in the last quarter. Blue Trust Inc. grew its stake in Integra LifeSciences by 100.5% during the 2nd quarter. Blue Trust Inc. now owns 886 shares of the life sciences company's stock valued at $26,000 after acquiring an additional 444 shares in the last quarter. CANADA LIFE ASSURANCE Co grew its stake in Integra LifeSciences by 1.1% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 49,762 shares of the life sciences company's stock valued at $1,764,000 after acquiring an additional 551 shares in the last quarter. Texas Permanent School Fund Corp grew its stake in Integra LifeSciences by 1.5% during the 1st quarter. Texas Permanent School Fund Corp now owns 59,524 shares of the life sciences company's stock valued at $2,110,000 after acquiring an additional 870 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Integra LifeSciences by 7.5% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,454 shares of the life sciences company's stock valued at $421,000 after acquiring an additional 1,010 shares in the last quarter. Hedge funds and other institutional investors own 84.78% of the company's stock.

Integra LifeSciences Stock Performance

Shares of IART traded down $0.73 during mid-day trading on Friday, hitting $24.78. The company's stock had a trading volume of 1,000,855 shares, compared to its average volume of 1,046,435. Integra LifeSciences Holdings Co. has a one year low of $16.81 and a one year high of $45.42. The company has a debt-to-equity ratio of 0.79, a quick ratio of 2.10 and a current ratio of 1.20. The firm has a market capitalization of $1.91 billion, a PE ratio of -275.30, a price-to-earnings-growth ratio of 0.91 and a beta of 1.08. The stock's 50-day moving average is $19.08 and its two-hundred day moving average is $24.38.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its earnings results on Monday, November 4th. The life sciences company reported $0.41 EPS for the quarter, beating analysts' consensus estimates of $0.39 by $0.02. The business had revenue of $380.80 million during the quarter, compared to analyst estimates of $375.81 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. Integra LifeSciences's revenue was down .4% on a year-over-year basis. During the same period in the prior year, the company posted $0.76 earnings per share. As a group, sell-side analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have weighed in on IART shares. JMP Securities lowered their target price on Integra LifeSciences from $40.00 to $35.00 and set a "market outperform" rating on the stock in a research note on Tuesday, July 30th. Bank of America lowered their target price on Integra LifeSciences from $26.00 to $18.00 and set an "underperform" rating on the stock in a research note on Monday, October 7th. Citigroup lifted their target price on Integra LifeSciences from $16.00 to $22.00 and gave the company a "sell" rating in a research note on Tuesday. Truist Financial lowered their price target on Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating for the company in a research note on Monday, October 14th. Finally, Morgan Stanley boosted their price target on Integra LifeSciences from $24.00 to $27.00 and gave the company an "underweight" rating in a research note on Monday, July 15th. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $27.25.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.